Embedded Files
Research Overview
Research Overview
Our laboratory investigates the molecular mechanisms of liver disease and drug-induced toxicity using human-relevant experimental models. Our research focuses on hepatic stellate cells, liver fibrosis, metabolic liver disease, hepatotoxicity, and organoid-based drug evaluation platforms. By integrating molecular biology, animal models, liver organoids, and multi-omics approaches, we aim to identify therapeutic targets and develop translational platforms for liver disease research and drug safety assessment.
- Hepatic Stellate Cells and Liver Fibrosis
Our laboratory investigates the molecular mechanisms that regulate hepatic stellate cell activation, inactivation, and fibrogenic responses. We aim to identify key transcriptional and signaling pathways that maintain the quiescent hepatic stellate cell phenotype and promote fibrosis regression.
Research interests
Molecular mechanisms regulating hepatic stellate cell quiescence and activation
Transcriptional networks involved in liver fibrosis and fibrosis regression
Anti-fibrotic mechanisms using liver organoid models
Discovery of therapeutic targets for liver fibrosis
2. Organoid-based Toxicity Evaluation Platform
2. Organoid-based Toxicity Evaluation Platform
Our laboratory develops liver organoid-based platforms to model liver fibrosis, metabolic liver disease, and drug-induced liver injury. We use these systems to evaluate the efficacy and toxicity of drug candidates and to establish human-relevant screening platforms for therapeutic discovery.
Research interests
Development of human and mouse liver organoid models
Organoid-based modeling of liver fibrosis and metabolic liver disease
Evaluation of anti-fibrotic and metabolic disease therapeutic candidates
Drug-induced hepatotoxicity assessment using organoid platforms
3. Animal Models of Liver Disease
3. Animal Models of Liver Disease
We investigate the role of specific genes in hepatic stellate cells and evaluate the therapeutic potential of candidate drugs, including anti-fibrotic agents and gene-targeting therapeutics, in animal models of liver fibrosis, metabolic liver disease, and liver cancer.
Research interests
Hepatic stellate cell-specific knockout mouse models
In vivo models of liver fibrosis progression and regression
Animal models of metabolic liver disease and liver cancer
Efficacy and safety evaluation of therapeutic candidates in vivo
Page updated
Report abuse